Clinical Trials Logo

Epicardial Fat clinical trials

View clinical trials related to Epicardial Fat.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04200625 Completed - Epicardial Fat Clinical Trials

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Start date: September 24, 2019
Phase:
Study type: Observational

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown